Kane Biotech Inc. (CVE:KNE – Get Free Report) shares reached a new 52-week low on Tuesday . The company traded as low as C$0.03 and last traded at C$0.03, with a volume of 1800 shares. The stock had previously closed at C$0.03.
Kane Biotech Price Performance
The company has a quick ratio of 0.39, a current ratio of 0.45 and a debt-to-equity ratio of -135.17. The business has a 50-day moving average price of C$0.03 and a 200-day moving average price of C$0.03. The firm has a market capitalization of C$6.15 million, a PE ratio of -3.00 and a beta of 0.97.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
See Also
- Five stocks we like better than Kane Biotech
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
